Publication Name	World Journal of Experimental Medicine
Manuscript ID	85302
Country	Italy

Received	2023-04-21 09:50
Peer-Review Started	2023-04-21 09:52
To Make the First Decision
Return for Revision	2023-05-15 08:38
Revised	2023-05-16 14:09
Second Decision	2023-06-16 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-06-16 08:41
Articles in Press	2023-06-16 08:41
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-06-13 03:58
Typeset the Manuscript	2023-08-25 02:57
Publish the Manuscript Online	2023-09-15 10:42

ISSN	2220-315x (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Letter to the Editor
Article Title	Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis
Manuscript Source	Invited Manuscript
All Author List	Marco Zeppieri
Funding Agency and Grant Number
Corresponding Author	Marco Zeppieri, BSc, MD, PhD, Doctor, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. markzeppieri@hotmail.com
Key Words	COVID-19; Hydroxychloroquine; SARS-CoV-2; Retinopathy; Maculopathy; Post-COVID-19 arthritis
Core Tip	Hydroxychloroquine (HCQ) is typically considered when treating rheumatic and autoimmune diseases. It has been currently considered to help treat symptoms of coronavirus disease 2019 and to help alleviate several clinical manifestations after infection. In this letter, several ophthalmological implications that should be taken into consideration when using this drug are discussed. While the drug may be beneficial in treating symptoms, ophthalmological manifestations can be of clinical importance. Proper diagnoses, periodic testing, and correct management of patients in chronic treatment with HCQ can ensure that any potential ophthalmological side effects are minimized.
Publish Date	2023-09-15 10:42
Citation	Zeppieri M. Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis. World J Exp Med 2023; 13(4): 95-98
URL	https://www.wjgnet.com/2220-315x/full/v13/i4/95.htm
DOI	https://dx.doi.org/10.5493/wjem.v13.i4.95

Full Article (PDF)	WJEM-13-95-with-cover.pdf
Full Article (Word)	WJEM-13-95.docx
Manuscript File	85302_Auto_Edited-JJW-WangTQ-JLW.docx
Answering Reviewers	85302-Answering reviewers.pdf
Audio Core Tip	85302-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	85302-Conflict-of-interest statement.pdf
Copyright License Agreement	85302-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	85302-Language certificate.pdf
Peer-review Report	85302-Peer-review(s).pdf
Scientific Misconduct Check	85302-Bing-Wang JJ-2.png
Scientific Editor Work List	85302-Scientific editor work list.pdf
CrossCheck Report	85302-CrossCheck report.pdf